HSTS

reCAPTCHA

IPv6

CloudFront

SiteGround CAPTCHA

Mobile Optimized

Akamai Hosted

Drupal

Adobe Dynamic Tag Management

Drupal 10

Chief Medical Officer

Douglas Kerr

President & CEO

Geoffrey Mcdonough

Chief Financial Officer

Matthew Norkunas

Chief Scientific Officer

Matthew Stanton

Business Management

Phillip Samayoa

Chief Development Officer (CDO)

Tracy Zimmermann

Vice President, People Development

Curtis Rising

VP, Head of Delivery

Di Bush

Vice President Regulatory Affairs and Medical Writing

Jennifer Dittman

VP of IT and Digital Strategy

Kim Pacheco

Jason Rhodes

Geoffrey McDonough

Ron Cooper

Geary MacQuiddy

Senior Director & Program Management

Andrew Scharenberg

Co-founder, Chair, Scientific Advisory Board

Antoinette Paone

Chief Operating Officer

Jon Voss

VP Quality Assurance

Co-Founder and Chief Strategy Officer

Gustav A. Christensen

Director

Biotechnology Companies With More Than 100 Employees

Greater Boston Area Companies With More Than $10M in Revenue

East Coast Companies With More Than 50 Employees (Top 10K)

East Coast Companies With Less Than $500M in Revenue (Top 10K)

Generation Bio is an innovative genetic medicines company focused on creating a new class of gene therapy to provide durable, redosable treatments for patients suffering from both rare and prevalent diseases. The company’s non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA; a novel cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The company is designing therapies to provide targeted delivery of genetic payloads that include large and multiple genes across a broad array of tissues, and to be redosable for individualized and extended treatment throughout a patient’s life. The platform is designed to expand access to treatments for rare diseases and to address prevalent diseases through efficient, scalable manufacturing.

Moderna

Post-IPO Equity - Generation Bio

T. Rowe Price

Series C - Generation Bio

Fidelity

Series B - Generation Bio

Atlas Venture

Series A - Generation Bio

Cambridge

Massachusetts

United States

North America

Generation Bio

Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market Evolution - Technavio

Generation Bio Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Generation Bio Co. Reports Q2 Loss, Tops Revenue Estimates

Generation Bio files for $600M mixed shelf

In the Green: Generation Bio Co (GBIO) Closes at 3.07, Up/Down -1.92 from Previous Day – DWinneX

Bullish insiders bet US$536k on Generation Bio Co. (NASDAQ:GBIO)

SG Americas Securities LLC Increases Stock Position in Generation Bio Co. (NASDAQ:GBIO)

Generation Bio Co. (GBIO) Reports Q4 Loss, Lags Revenue Estimates

Generation Bio: Too Late To Pivot? (NASDAQ:GBIO)

Insiders See US$778.9k Investment In Generation Bio Jump Last Week

A DNA construct designed to carry large or multiple genes to cells, potentially treating a wide range of diseases with durable expression.

A cell-targeted lipid nanoparticle delivery system engineered for specific tissue targeting, enabling personalized and redosable treatments.

A rapid enzymatic synthesis manufacturing process that produces highly pure DNA constructs efficiently, aiming for global access to genetic medicines.

HTML5

jQuery

Microsoft Outlook

GoDaddy Premium DNS

Google Fonts

F5 NGINX

Google Tag Manager

Adobe Fonts

Vimeo

Wordpress

Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Generation Bio Co.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Mar 8, 2024 11:39 AM	55531ff2
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 8, 2024 11:39 AM	842442b8
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	178a36a5
crunchbase profile	general	Nov 25, 2024 9:42 AM	64e82e98
li profile	general
translate crunchbase fundingrounds	general	Nov 25, 2024 1:53 PM	78ac3881
peers	general
news basic	general	Mar 8, 2024 11:39 AM	5aea92d4
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:GENERATIONBIO

Generation Bio Co.

Last Close

1.32

22/11 21:00

Market Cap

155.01M

Beta: -

Volume Today

326.95K

Avg: -